Evidence map›Paper›PMID 41835969›Full record

ArticleGMS hygiene and infection control2026

Randomized controlled clinical trial of the impact of combined application of rhamnosus probiotics and oral nystatin on the colonization of intestinal Candida albicans in low birth weight neonates <2,500 grams.

Mazyar Vakiliamini, Reza Habibi, Samira Zarei, Roya Chegene Lorestani, Fatemeh Rezaeeniya, Farzad Mashreghi, Pourya Mohammadi, Mansour Rezaei, Mosayeb Rostamian, Hajar Motamed

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in GMS hygiene and infection control, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mazyar VakiliaminiClinical Research Development Center, Imam Khomeini and Mohammad Kermanshahi and Farabi Hospitals, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Reza HabibiClinical Research Development Center, Imam Khomeini and Mohammad Kermanshahi and Farabi Hospitals, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Samira ZareiDepartment of Microbiology, School of Sciences, Kherad Institute of Higher Education, Bushehr, Iran.
Roya Chegene LorestaniInfectious Diseases Research Center, Health Policy and Promotion Institute, Kermanshah University of Medica Sciences, Kermanshah, Iran.
Fatemeh RezaeeniyaSchool of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
Farzad MashreghiClinical Research Development Center, Imam Khomeini and Mohammad Kermanshahi and Farabi Hospitals, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Pourya MohammadiDepartment of Parasitology, School of Medicine, Qazvin University of Medical Sciences, Gazvin, Iran.
Mansour RezaeiDepartment of Biostatistics, School of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Mosayeb RostamianInfectious Diseases Research Center, Health Policy and Promotion Institute, Kermanshah University of Medica Sciences, Kermanshah, Iran.
Hajar MotamedDepartment of Pathology, School of Medicine, Kermanshah University of Medical Sciences Kermanshah, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study aimed to evaluate the concurrent effects of consuming Rhamnosus probiotics and oral antifungal Nystatin on inhibiting Materials: This study was a randomized controlled clinical trial conducted on 104 infants born weighing <2,500 grams at Mohammad Kermanshahi Hospital in Kermanshah in 2021-22. The infants were randomly allocated into intervention (n=52) and control (n=52) groups. The control group received a placebo, 10 drops orally four times daily. In contrast, the intervention group received oral Nystatin 100,000 units 10 drops three times a day, combined with Rhamnosus Lactobacillus oral drops once daily for 7 to 10 days. Results: The results showed a lower frequency of positive Discussion: The concurrent use of Rhamnosus probiotics and oral Nystatin can lead to a reduction of positive

Indexed as

Candida albicansenteral colonizationfewer NPO daysimproved food intakeneonatesoral nystatinRhamnosus probioticsshortened hospital stay

Identifiers

PMID41835969
PMCPMC12981032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.